Associated Papers
Analysis of the Relationship Between EGFR Mutations and PD-L1, ALK, and ROS1 Alterations in Patients with Non- Small-Cell Lung Cancer: The Most Extensive Study Conducted in Iran.
Hadimaleki S et al.
Turk Patoloji Dergisi, 2025
PD-L1 expression and immune profiling cannot predict osimertinib efficacy in lung cancer with EGFR T790 M mutation: A translational study.
Yang CY et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi, 2024
The Epidermal Growth Factor, Anaplastic Lymphoma Kinase, and ROS Proto-oncogene 1 Mutation Profile of Non-Small Cell Lung Carcinomas in the Turkish Population: A Single-Center Analysis.
Gün E et al.
Thoracic Research and Practice, 2024
Clinical significance of TP53 alterations in advanced NSCLC patients treated with EGFR, ALK and ROS1 tyrosine kinase inhibitors: An update.
Moes-Sosnowska J et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine, 2024
Non-Small Cell Lung Cancer: Targetable Variants in Concurrent Tissue and Liquid Biopsy Testing in a North Indian Cohort.
Paturu R et al.
Asian Pacific Journal of Cancer Prevention : Apjcp, 2023
The Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Clinical Application of New Therapeutic Strategies.
Laface C et al.
Pharmaceutics, 2023
Two Unusual Mutations in the Epidermal Growth Factor Receptor Gene in a Patient With Lung Adenocarcinoma.
Zapata Laguado M et al.
Cureus, 2022
Genomic characteristics of driver genes in Chinese patients with non-small cell lung cancer.
Si X et al.
Thoracic Cancer, 2021
Tumor Mutation Burden and Differentially Mutated Genes Among Immune Phenotypes in Patients with Lung Adenocarcinoma.
Wang H et al.
Oncotargets and Therapy, 2021
Genetic profiling of primary and secondary tumors from patients with lung adenocarcinoma and bone metastases reveals targeted therapy options.
Huang L et al.
Molecular Medicine (cambridge, Mass.), 2020
Effect of icotinib on advanced lung adenocarcinoma patients with sensitive EGFR mutation detected in ctDNA by ddPCR.
Chen HF et al.
Translational Cancer Research, 2019
Molecular profile of non-small cell lung cancer in northeastern Brazil.
Oliveira ACDSM et al.
Jornal Brasileiro De Pneumologia : Publicacao Oficial Da Sociedade Brasileira De Pneumologia E Tisilogia, 2019
Impact of smoking on frequency and spectrum of K-RAS and EGFR mutations in treatment naive Indonesian lung cancer patients.
Masykura N et al.
Lung Cancer (auckland, N.z.), 2019
Epidermal Growth Factor Receptor (EGFR) Mutations and Anaplastic Lymphoma Kinase/Oncogene or C-Ros Oncogene 1 (ALK/ROS1) Fusions Inflict Non-Small Cell Lung Cancer (NSCLC) Female Patients Older Than 60 Years of Age.
Ke L et al.
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research, 2018
Concomitant EML4-ALK rearrangement and EGFR mutation in non-small cell lung cancer patients: a literature review of 100 cases.
Lo Russo G et al.
Oncotarget, 2017
Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma.
Tanaka K et al.
Cancer, 2017
Concurrent gene alterations with EGFR mutation and treatment efficacy of EGFR-TKIs in Chinese patients with non-small cell lung cancer.
Hu W et al.
Oncotarget, 2017
Distinct epithelial growth factor receptor mutation profile in non-small-cell lung cancer patients from the Xuanwei area of China.
Chen Y et al.
Molecular and Clinical Oncology, 2016
Clinical characteristics of patients with non-small cell lung cancers harboring anaplastic lymphoma kinase rearrangements and primary lung adenocarcinoma harboring epidermal growth factor receptor mutations.
Xu L et al.
Genetics and Molecular Research : Gmr, 2015
Management of EGFR mutated nonsmall cell lung carcinoma patients.
Grigoriu B et al.
The European Respiratory Journal, 2015
Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review.
Stewart EL et al.
Translational Lung Cancer Research, 2015
Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort.
Yano S et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2011
Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer.
Mitsudomi T et al.
The Febs Journal, 2010
ALK, ROS1 and EGFR status of lung cancers in the Aegean Region of Turkey.
Diniz G et al.
Indian Journal of Pathology & Microbiology, 0